tradingkey.logo
tradingkey.logo
Search

Amylyx Pharmaceuticals Inc

AMLX
Add to Watchlist
20.310USD
-0.440-2.12%
Close 07-31 16:00ETQuotes delayed by 15 min
2.26BMarket Cap
LossP/E TTM

AMLX Income Statement

You can find the annual or quarterly income statement of Amylyx Pharmaceuticals Inc here for insights into the performance and operational efficiency of Amylyx Pharmaceuticals Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q2
FY2021Q1
FY2020Q4
Total revenue
--0.00
100.00%0.00
-100.00%0.00
100.00%0.00
-100.00%0.00
-100.61%-665.00K
-99.59%416.00K
-101.04%-1.02M
24.10%88.64M
395.54%108.45M
29666.09%102.69M
--98.22M
--71.43M
--21.89M
--345.00K
----
----
-100.00%0.00
----
----
--350.00K
Revenue
--0.00
100.00%0.00
-100.00%0.00
100.00%0.00
-100.00%0.00
-100.61%-665.00K
-99.59%416.00K
-101.04%-1.02M
24.10%88.64M
395.54%108.45M
29666.09%102.69M
--98.22M
--71.43M
--21.89M
--345.00K
----
----
-100.00%0.00
----
----
--350.00K
Cost of revenue
--0.00
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-84.50%809.00K
32.94%7.42M
352.51%23.91M
231.80%9.36M
2933.72%5.22M
--5.58M
--5.28M
--2.82M
--172.00K
----
----
----
----
----
----
Operating expenses
15.81%43.78M
-9.96%36.60M
-9.65%36.03M
-18.23%42.86M
-68.04%37.80M
-61.83%40.65M
-52.52%39.87M
-32.82%52.41M
60.96%118.27M
60.23%106.52M
52.61%83.97M
43.80%78.02M
53.68%73.48M
134.78%66.48M
--55.03M
191.89%54.25M
271.57%47.81M
216.65%28.32M
--18.59M
--12.87M
--8.94M
R&D expenses
24.82%27.61M
-7.33%21.21M
-6.51%19.86M
16.58%27.22M
-39.58%22.12M
-49.03%22.89M
-29.30%21.24M
-19.62%23.35M
51.32%36.61M
96.88%44.91M
20.56%30.04M
19.72%29.04M
12.71%24.19M
70.32%22.81M
--24.91M
121.97%24.26M
212.70%21.46M
167.19%13.39M
--10.93M
--6.86M
--5.01M
Depreciation, depletion, and amortization
-37.18%98.00K
-32.50%108.00K
-45.70%120.00K
-32.21%141.00K
-50.48%156.00K
-46.84%160.00K
-26.82%221.00K
-25.98%208.00K
54.41%315.00K
65.38%301.00K
83.03%302.00K
167.62%281.00K
482.86%204.00K
727.27%182.00K
--165.00K
950.00%105.00K
250.00%35.00K
2100.00%22.00K
--10.00K
--10.00K
--1.00K
Other operating expenses
--16.86M
----
----
----
----
--665.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating profit
-15.81%-43.78M
9.96%-36.60M
8.70%-36.03M
19.80%-42.86M
-27.58%-37.80M
-2202.07%-40.65M
-310.78%-39.46M
-364.52%-53.44M
-1343.25%-29.63M
104.34%1.93M
134.23%18.72M
137.23%20.20M
95.71%-2.05M
-57.49%-44.59M
---54.68M
-191.89%-54.25M
-271.57%-47.81M
-229.55%-28.32M
---18.59M
---12.87M
---8.59M
Net non-operating interest income (expenses)
Non-operating interest income
15.19%2.57M
42.06%3.29M
-41.22%1.82M
-51.83%1.96M
-48.43%2.23M
-47.01%2.32M
-25.87%3.10M
4.68%4.07M
16.35%4.33M
38.45%4.37M
595.34%4.18M
866.92%3.89M
2738.17%3.72M
10423.33%3.16M
--601.00K
40100.00%402.00K
6450.00%131.00K
--30.00K
--1.00K
--2.00K
--0.00
Non-operating interest expense
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-100.00%0.00
----
----
--1.00K
Special income (expenses)
----
--0.00
100.00%0.00
100.00%0.00
----
--0.00
---36.20M
---22.85M
---92.50M
--0.00
----
----
----
--0.00
--0.00
100.00%0.00
100.00%0.00
--0.00
---3.31M
---1.92M
--0.00
Other non-operating income (expenses)
77.61%-75.00K
130.57%362.00K
-27.66%-180.00K
-13.04%-546.00K
55.15%-335.00K
-8.19%157.00K
71.11%-141.00K
-496.30%-483.00K
-185.11%-747.00K
124.82%171.00K
-345.23%-488.00K
-92.86%-81.00K
-1278.95%-262.00K
-1067.80%-689.00K
--199.00K
-61.54%-42.00K
-107.28%-19.00K
-6000.00%-59.00K
---26.00K
--261.00K
--1.00K
Income before tax
-14.97%-41.28M
13.69%-32.95M
52.70%-34.39M
42.99%-41.44M
69.71%-35.91M
-689.58%-38.18M
-424.41%-72.70M
-402.83%-72.70M
-8549.82%-118.55M
115.37%6.48M
141.59%22.41M
144.55%24.01M
102.94%1.40M
-48.62%-42.13M
---53.88M
-145.84%-53.89M
-228.46%-47.70M
-229.89%-28.34M
---21.92M
---14.52M
---8.59M
Income tax
----
107.24%46.00K
--0.00
--0.00
-100.00%0.00
-136.39%-635.00K
----
-100.00%0.00
242.35%242.00K
201.38%1.75M
1314.40%1.52M
1010.92%1.93M
-216.44%-170.00K
--579.00K
---125.00K
--174.00K
--146.00K
----
--0.00
--0.00
----
Income after tax
-14.97%-41.28M
12.11%-33.00M
52.70%-34.39M
42.99%-41.44M
69.77%-35.91M
-893.62%-37.55M
-447.98%-72.70M
-429.35%-72.70M
-7652.00%-118.79M
111.08%4.73M
138.87%20.89M
140.83%22.07M
103.29%1.57M
-50.66%-42.70M
---53.76M
-146.63%-54.07M
-229.46%-47.85M
-229.89%-28.34M
---21.92M
---14.52M
---8.59M
Net income from continuous operations
-14.97%-41.28M
12.11%-33.00M
52.70%-34.39M
42.99%-41.44M
69.77%-35.91M
-893.62%-37.55M
-447.98%-72.70M
-429.35%-72.70M
-7652.00%-118.79M
111.08%4.73M
138.87%20.89M
140.83%22.07M
103.29%1.57M
-50.66%-42.70M
---53.76M
-146.63%-54.07M
-229.46%-47.85M
-229.89%-28.34M
---21.92M
---14.52M
---8.59M
Net income attributable to controlling interests
-14.97%-41.28M
12.11%-33.00M
52.70%-34.39M
42.99%-41.44M
69.77%-35.91M
-893.62%-37.55M
-447.98%-72.70M
-429.35%-72.70M
-7652.00%-118.79M
111.08%4.73M
138.87%20.89M
140.83%22.07M
103.29%1.57M
-50.66%-42.70M
---53.76M
-146.63%-54.07M
-229.46%-47.85M
-229.89%-28.34M
---21.92M
---14.52M
---8.59M
Net income attributable to common shareholders
-14.97%-41.28M
12.11%-33.00M
52.70%-34.39M
42.99%-41.44M
69.77%-35.91M
-893.62%-37.55M
-447.98%-72.70M
-429.35%-72.70M
-7652.00%-118.79M
111.08%4.73M
138.87%20.89M
140.83%22.07M
103.29%1.57M
-50.66%-42.70M
---53.76M
-146.63%-54.07M
-229.46%-47.85M
-229.89%-28.34M
---21.92M
---14.52M
---8.59M
Basic earnings per share
10.88%-0.37
45.20%-0.30
65.50%-0.37
56.50%-0.46
76.07%-0.42
-881.69%-0.55
-444.52%-1.07
-425.51%-1.07
-7524.55%-1.75
110.74%0.07
133.75%0.31
135.39%0.33
102.54%0.02
-29.90%-0.65
---0.92
-138.98%-0.93
-260.50%-0.93
-229.90%-0.50
---0.39
---0.26
---0.15
Diluted earnings per share
10.88%-0.37
45.20%-0.30
65.50%-0.37
56.50%-0.46
76.07%-0.42
-904.44%-0.55
-456.45%-1.07
-439.55%-1.07
-7986.08%-1.75
110.43%0.07
132.62%0.30
133.93%0.31
102.39%0.02
-29.90%-0.65
---0.92
-138.98%-0.93
-260.50%-0.93
-229.90%-0.50
---0.39
---0.26
---0.15
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Amylyx Pharmaceuticals Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing AMLX stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Amylyx Pharmaceuticals Inc's net income for the year?

Amylyx Pharmaceuticals Inc posted -144.74M in net income for fiscal year 2025.

How much net income did Amylyx Pharmaceuticals Inc post in the last quarter?

Amylyx Pharmaceuticals Inc reported -41.28M in net income for the latest quarter。

What was Amylyx Pharmaceuticals Inc's annual operating profit?

Amylyx Pharmaceuticals Inc's operating income was -153.29M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.